TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04576949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisinicline
Description: film-coated oral tablets containing 3 mg cytisinicline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisinicline
Description: film-coated oral tablets containing 3 mg cytisinicline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: film-coated oral tablets containing matched placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: film-coated oral tablets containing matched placebo

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral support
Description: Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the subject about their attempt to quit smoking. Each session will last approximately 10 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral support
Description: Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the subject about their attempt to quit smoking. Each session will last approximately 10 minutes.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral support
Description: Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the subject about their attempt to quit smoking. Each session will last approximately 10 minutes.
Study: NCT01066442

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BF2.649 (Pitolisant)
Description: 1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D
Study: NCT02924402

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb13676
Description: Biological

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb13676
Description: Biological

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb13676
Description: Biological

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb13676
Description: Biological

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb13676
Description: Biological

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb13676
Description: Biological
Study: NCT04969107

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: taTME
Description: Resection of rectal cancer with preparation of the mesorectal plane along the TME-plane in a rendezvous procedure of an abdominal and a transanal approach.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: abdTME
Description: Resection of rectal cancer with preparation of the mesorectal plane along the TME-plane in an abdominal Approach.
Study: NCT02187081

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation plus Sorafenib
Description: To treat HCC with the combination of radiofrequency ablation and sorafenib

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: To treat HCC with radiofrequency ablation alone.
Study: NCT01687205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Tenofovir Gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Tenofovir Gel
Study: NCT02113046

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pancreatico-jejunal anastomosis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional anastomosis
Study: NCT00420407

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline control
Description: no vasopressin added to bolus or 5 hour continuous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vasopressin
Description: vasopressin bolus 4 units followed by continuous infusion 2.4units/hr for 5 hours
Study: NCT04545489

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: This is a intervention for 12 months which focuses on behavioral and medication management, led by a health coach (nurse or pharmacist)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education control group
Description: This group will receive education materials related to CVD risk reduction at each 4 month visit over the course of 12 months.
Study: NCT01849848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SyB L-0501
Description: The administration of SyB L-0501 at 90 mg/m\^2/day by 60-minute intravenous infusion for 2 consecutive days followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 times. Dose reduction or discontinuation is permitted from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle.
Study: NCT02584569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-915
Description: TAK-915 oral suspension
Study: NCT02047123

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Raw Flaxseed
Description: The participants were randomly single blind controlled trial distributed into three groups: (1, n =30), (2, n =32), (3, n =27). For 30 days, participants in group 1 took with 15g flaxseed mixed with yoghurt and diet,(the 15g of flaxseed that was provided in addition to the linen package spoon so all would take far it) group 2 took yoghurt and diet, and group 3 only received the diet.
Study: NCT02725385

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Physiologic Testing
Description: Undergo Trier Social Stress Test

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study: NCT03384511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Patients will accept apatinib therapy and undergo baseline 18F-ALF-NOTA-PRGD2 PET/CT scans of the whole body after having met all eligibility criterias.
Study: NCT02562196

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tdcs
Description: The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tdcs
Description: The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.~To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds.
Study: NCT04795440

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Testicular biopsy
Description: Performance of a testicular biopsy with the intention of obtaining spermatozoa for the insemination of oocytes with the ICSI technique.
Study: NCT03396471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg IV at day -21, then day 1 of each 21-day cycle for a maximum of 24 continuous months of Pembrolizumab (35 cycles) from Cycle 1 Day 1 (C1D1) can be administered.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: 20-30 Gy over five fractions for up to two cycles.
Study: NCT00200148

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normovolemic Hemodilution (ANH)
Description: For those patients randomized to ANH, the pre-calculated volume of blood will be withdrawn to a target hemoglobin of 8.0 - 8.5 g/dl (maximum of 3 L) using the formula VL=EBV x (HO-HF)/Hav, as above. The removed blood will be stored in a standard citrate-phosphate-dextrose buffer solution in blood storage bags in the operating room. During removal of blood, colloid and crystalloid solutions will be administered via peripheral intravenous lines in order to maintain euvolemia. For all patients, arterial blood will be sampled every 30 minutes during the resection for assessment of arterial blood gases/pH; Hgb levels will be measured every 30 minutes.For patients randomized to ANH, autologous blood will be re-infused in the reverse order from which it was removed, and allogeneic blood will given only after all autologous blood has been given.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: An 8.5 French central venous catheter and an arterial line will be placed in all patients. If the patient has a central line already in place, this may be used in place of the 8.5 French internal jugular catheter. Continuous monitoring of heart rate, blood pressure, ECG (II, V5), CVP, end tidal CO2, oxygen saturation, temperature and urine output will be performed for all patients.For all hepatic resections, standard low CVP anesthetic management will be employed.For all patients, arterial blood will be sampled every 30 minutes during the resection for assessment of arterial blood gases/pH; Hgb levels will be measured every 30 minutes.All patients will receive standard postoperative management. Routine laboratory studies, including comprehensive panel, CBC and coagulation profile, will be obtained daily in the post-operative period.
Study: NCT02777840

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: face mask oxygen
Description: oxygen given by face mask as per routine practice

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High flow oxygen
Description: High flow oxygen given via optiflo machine / device
Study: NCT04143880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: intramuscular injection intranasal administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: intramuscular injection intranasal administration
Study: NCT03028545

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Collection of the individual narrative, semi-directed interviews
Description: Visit one : individual interview Individual narrative Passing Psychometric Measurement Scales of Recovery: Score at Warwick and Wellness Scale Andreasen scale score Visit two Focus group

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Collection of the individual narrative, semi-directed interviews
Description: Visit one : individual interview Individual narrative Passing Psychometric Measurement Scales of Recovery: Score at Warwick and Wellness Scale Andreasen scale score Visit two Focus group

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Collection of the individual narrative, semi-directed interviews
Description: Visit one : individual interview Individual narrative Passing Psychometric Measurement Scales of Recovery: Score at Warwick and Wellness Scale Andreasen scale score Visit two Focus group

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Collection of the individual narrative, semi-directed interviews
Description: Visit one : individual interview Individual narrative Passing Psychometric Measurement Scales of Recovery: Score at Warwick and Wellness Scale Andreasen scale score Visit two Focus group
Study: NCT01258270

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postop Dressing
Description: The AQUACEL® Ag Surgical Dressing is a silver impregnated, waterproof, adhesive dressing that sticks to the skin around the wound and blocks bacteria from the outside.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postop Dressing
Description: A standard island dressing consists of adhesive tape and gauze.
Study: NCT03762538

Intervention type: DRUG
Intervention: Propofol
Description: Patients will be induced to unconsciousness using propofol intravenously.

Intervention type: DRUG
Intervention: Propofol
Description: Patients will be induced to unconsciousness using propofol intravenously.
Study: NCT02690402

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: adapted physical activity
Description: The study begins with an evaluation of physical strenght and cognitive and psychometric assessment.Then, a personalized care will be offered in terms of adapted physical activity. The evaluation protocol will be performed again to measure the impact of physical activity three months after the first assessment.
Study: NCT04344288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: The experimental group will receive oral prednisone during 10 days (0.75 mg/kg/day during 5 days then 20 mg/day during 5 more days)

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: The control group will receive standard of care according to the international recommendations and practices of the investigational site. No corticosteroid therapy can be prescribed in this group.
Study: NCT01837771

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diaphragmatic stimulation
Study: NCT03583203

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: personalized information about lung damage
Description: Chronic obstructive pulmonary disease (COPD) will be evaluated using spirometry. Based on this value, a motivational message about prevention will be issued for the intervention group, which will be reinforced by individualized text messages over a period of 3 months
Study: NCT04188626

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Driving simulator sessions
Description: The volunteers will be placed in a driving simulator that will simulate autonomous highway driving. This autonomous driving will be interrupted by take-over requests related to events that disrupt autonomous driving. During autonomous driving, the driver will have to disengage from driving by performing non-related driving tasks. During each non-related driving tasks, a take-over request will be sent. Electrophysiological (EEG, ECG, EDA, EMG, respiration) and behavioural data will be recorded before, during and after the take-over control.
Study: NCT04195477

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: vDPP
Description: virtual Diabetes Prevention Program
Study: NCT04079374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Subcutaneous injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enbrel
Description: Subcutaneous injections
Study: NCT00280293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Lamotrigine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03072082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danlou Tablet
Description: Conventional western medicine \& Danlou Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DanLou Tablet placebo
Description: Conventional western medicine \& placebo (for Danlou Tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin Enteric-coated Tablets
Description: 100 mg tablet, one tablet daily.
Study: NCT02563873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tailored pacemaker settings
Description: Tailored pacemaker settings, optimised for cardiac contractility: Pacemaker settings, optimised for cardiac contractility as determined by echocardiography, will be programmed
Study: NCT05000606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A home visit program
Description: A home visit program including education and counseling was applied. A total of five home visits over three months were performed.
Study: NCT01652677

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation is a noninvasive technique for including electrical currents in the cerebral cortex by means of time-varying magnetic fields.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation is a noninvasive technique for including electrical currents in the cerebral cortex by means of time-varying magnetic fields.
Study: NCT03072082

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin Enteric-coated Tablets
Description: 100 mg tablet, one tablet daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet
Description: One tablet daily. (for patients who can't use aspirin)
Study: NCT01652677

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation is a noninvasive technique for including electrical currents in the cerebral cortex by means of time-varying magnetic fields.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Transcranial magnetic stimulation
Description: Transcranial magnetic stimulation is a noninvasive technique for including electrical currents in the cerebral cortex by means of time-varying magnetic fields.
Study: NCT02501863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Femoral nerve block with ropivacaine+fentanyl
Description: Ropivacaine+fentanyl are used for continuous femoral nerve block, spinal anesthesia, IV-PCA with hydromorphone
Study: NCT01355991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: 18mcg/ capsule inhaled once daily for two weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: 50mcg inhalation twice daily for two weeks
Study: NCT04283461

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike protein 2019-nCoV. mRNA-1273 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, DSPC, and PEG2000 DMG.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike protein 2019-nCoV. mRNA-1273 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, DSPC, and PEG2000 DMG.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike protein 2019-nCoV. mRNA-1273 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, DSPC, and PEG2000 DMG.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike protein 2019-nCoV. mRNA-1273 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, DSPC, and PEG2000 DMG.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike protein 2019-nCoV. mRNA-1273 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, DSPC, and PEG2000 DMG.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1273
Description: Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike protein 2019-nCoV. mRNA-1273 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, DSPC, and PEG2000 DMG.
Study: NCT02501863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Femoral nerve block with ropivacaine
Description: Ropivacaine is used for continuous femoral nerve block, spinal anesthesia, IV-PCA with hydromorphone
Study: NCT03237312

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic ovarian drilling
Description: The electric current used was set at 40 Watts. The power was activated just before touching the ovary, and then the needle electrode was held against the antimesenteric surface of the ovary for 4 seconds until penetration of the ovarian capsule. Four or eight puncture points were made through the ovarian capsule of each ovary according to the study protocol. The ovaries were cooled in the pool of the Ringer's lactate after each cauterization both to minimize adhesion formation and to prevent heat trauma to the adjacent viscera. Complete hemostasis was ensured. At the end of the procedure, the ovaries were copiously rinsed with Ringer's lactate (Aqua-purator, Storz, Germany). An amount about 200 ml of heparinized Ringers lactate (5000 IU/1000 ml) was left in the pelvis to avoid postoperative adhesions.
Study: NCT03072082

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet
Description: One tablet daily. (for patients who can't use aspirin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin calcium
Description: 10 mg tablet, two tablets each night.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin calcium
Description: 10 mg tablet, two tablets each night.